We are live on ! Find out more
ATXI

Avenue Therapeutics, Inc. Common Stock
ATXI

Delisted

ATXI was delisted on the 18th of March, 2025.

Back to rankings

15 hedge funds and large institutions have $181K invested in Avenue Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

7% more funds holding

Funds holding: 14 → 15 (+1)

64% less capital invested

Capital invested by funds: $503K → $181K (-$322K)

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Holders
15
Holders Change
+1
Holders Change %
+7.14%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$42.8K
2
HF
HRT Financial
New York
+$13.5K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$8.86K
4
Wells Fargo
Wells Fargo
California
+$6.93K
5
CAN
Cetera Advisor Networks
California
+$3.85K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$110K
2
Citadel Advisors
Citadel Advisors
Florida
-$57K
3
VF
Virtu Financial
New York
-$28K
4
TRCT
Tower Research Capital (TRC)
New York
-$10K
5
TSS
Two Sigma Securities
New York
-$9.24K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$36K -$110K -285 -71%
Renaissance Technologies
2
Renaissance Technologies
New York
$34K +$42.8K +111 New
Geode Capital Management
3
Geode Capital Management
Massachusetts
$22K – – –
Wells Fargo
4
Wells Fargo
California
$18K +$6.93K +18 +42%
BRWA
5
B. Riley Wealth Advisors
Florida
$16K -$770 -2 -4%
HF
6
HRT Financial
New York
$10K +$13.5K +35 New
UBS Group
7
UBS Group
Switzerland
$9K – – –
TSS
8
Two Sigma Securities
New York
$7K -$9.24K -24 -51%
BlackRock
9
BlackRock
New York
$7K -$8.86K -23 -47%
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$7K +$8.86K +23 New
EL
11
EMFO LLC
Florida
$4K -$2.7K -7 -33%
Northern Trust
12
Northern Trust
Illinois
$4K – – –
Millennium Management
13
Millennium Management
New York
$3K – – –
CAN
14
Cetera Advisor Networks
California
$3K +$3.85K +10 New
TRCT
15
Tower Research Capital (TRC)
New York
$1K -$10K -26 -90%
BNP Paribas Financial Markets
16
BNP Paribas Financial Markets
France
$2 – – –
Citadel Advisors
17
Citadel Advisors
Florida
– -$57K -105 Closed
VF
18
Virtu Financial
New York
– -$28K -52 Closed

ATXI Hedge Fund Activity: Q2 2022 in Review

15 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q2 2022, worth a combined $181K — down 64% from $503K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ATXI positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 6 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $42.8K. The largest seller was Vanguard Group, cutting an estimated $110K.

  • 15 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q2 2022, up from 14 in Q1 2022.
  • Funds reported $181K of Avenue Therapeutics, Inc. Common Stock stock for Q2 2022, down 64% quarter-over-quarter.
  • 4 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q2 2022 and 3 closed out, a net change of +1 holder.
  • The largest Avenue Therapeutics, Inc. Common Stock buyer in Q2 2022 was Renaissance Technologies, an estimated $42.8K added.
  • The largest Avenue Therapeutics, Inc. Common Stock seller in Q2 2022 was Vanguard Group, an estimated $110K sold.

Based on aggregated 13F filings for Q2 2022.